Charles H Lawrie1, Adrian L Harris2, Esther Arnaiz2, Ana Miar3, Esther Bridges2, Naveen Prasad4, Stephanie B Hatch5, Daniel Ebner5. 1. Department of Oncology, Molecular Oncology Group, Biodonostia Health Research Institute, Paseo Doctor Begiristain s/n, 20014, San-Sebastián, Spain. 2. Department of Medical Oncology, Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, OX3 9DS, UK. 3. Department of Oncology, Old Road Campus Research Building, University of Oxford, Oxford, OX3 7DQ, UK. anbelen_mc@hotmail.com. 4. Department of Oncology, Old Road Campus Research Building, University of Oxford, Oxford, OX3 7DQ, UK. 5. Nuffield Department of Medicine, NDM Research Building, University of Oxford, Oxford, OX3 7DQ, UK.
Abstract
BACKGROUND: In clear cell renal cell carcinoma, 80% of cases have biallelic inactivation of the VHL gene, leading to constitutive activation of both HIF1α and HIF2α. As HIF2α is the driver of the disease promoting tumour growth and metastasis, drugs targeting HIF2α have been developed. However, resistance is common, therefore new therapies are needed. METHODS: We assessed the effect of the HIF2α antagonist PT2385 in several steps of tumour development and performed RNAseq to identify genes differentially expressed upon treatment. A drug screening was used to identify drugs with antiproliferative effects on VHL-mutated HIF2α-expressing cells and could increase effectiveness of PT2385. RESULTS: PT2385 did not reduce cell proliferation or clonogenicity but, in contrast to the genetic silencing of HIF2α, it reduced in vitro cell invasion. Many HIF-inducible genes were down-regulated upon PT2385 treatment, whereas some genes involved in cell migration or extracellular matrix were up-regulated. HIF2α was associated with resistance to statins, addition to PT2385 did not increase the sensitivity. CONCLUSIONS: this study shows key differences between inhibiting a target versus knockdown, which are potentially targetable.
BACKGROUND: In clear cell renal cell carcinoma, 80% of cases have biallelic inactivation of the VHL gene, leading to constitutive activation of both HIF1α and HIF2α. As HIF2α is the driver of the disease promoting tumour growth and metastasis, drugs targeting HIF2α have been developed. However, resistance is common, therefore new therapies are needed. METHODS: We assessed the effect of the HIF2α antagonist PT2385 in several steps of tumour development and performed RNAseq to identify genes differentially expressed upon treatment. A drug screening was used to identify drugs with antiproliferative effects on VHL-mutated HIF2α-expressing cells and could increase effectiveness of PT2385. RESULTS:PT2385 did not reduce cell proliferation or clonogenicity but, in contrast to the genetic silencing of HIF2α, it reduced in vitro cell invasion. Many HIF-inducible genes were down-regulated upon PT2385 treatment, whereas some genes involved in cell migration or extracellular matrix were up-regulated. HIF2α was associated with resistance to statins, addition to PT2385 did not increase the sensitivity. CONCLUSIONS: this study shows key differences between inhibiting a target versus knockdown, which are potentially targetable.
Authors: Raju R Raval; Kah Weng Lau; Maxine G B Tran; Heidi M Sowter; Stefano J Mandriota; Ji-Liang Li; Christopher W Pugh; Patrick H Maxwell; Adrian L Harris; Peter J Ratcliffe Journal: Mol Cell Biol Date: 2005-07 Impact factor: 4.272
Authors: Luana Schito; Sergio Rey; Marco Tafani; Huafeng Zhang; Carmen Chak-Lui Wong; Andrea Russo; Matteo A Russo; Gregg L Semenza Journal: Proc Natl Acad Sci U S A Date: 2012-09-10 Impact factor: 11.205
Authors: John D Gordan; Priti Lal; Vijay R Dondeti; Richard Letrero; Krishna N Parekh; C Elisa Oquendo; Roger A Greenberg; Keith T Flaherty; W Kimryn Rathmell; Brian Keith; M Celeste Simon; Katherine L Nathanson Journal: Cancer Cell Date: 2008-12-09 Impact factor: 31.743
Authors: Umberto Capitanio; Karim Bensalah; Axel Bex; Stephen A Boorjian; Freddie Bray; Jonathan Coleman; John L Gore; Maxine Sun; Christopher Wood; Paul Russo Journal: Eur Urol Date: 2018-09-19 Impact factor: 20.096
Authors: Sakari Vanharanta; Weiping Shu; Fabienne Brenet; A Ari Hakimi; Adriana Heguy; Agnes Viale; Victor E Reuter; James J-D Hsieh; Joseph M Scandura; Joan Massagué Journal: Nat Med Date: 2012-12-09 Impact factor: 53.440